Nektar Historical Cash Flow
| NKTR Stock | USD 0.76 0.04 5.00% |
Analysis of Nektar Therapeutics cash flow over time is an excellent tool to project Nektar Therapeutics future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Capital Expenditures of 1.4 M or Total Cash From Financing Activities of 40 M as it is a great indicator of Nektar Therapeutics ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Nektar Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Nektar Therapeutics is a good buy for the upcoming year.
Nektar |
About Nektar Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Nektar balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Nektar's non-liquid assets can be easily converted into cash.
Nektar Therapeutics Cash Flow Chart
Add Fundamental
Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Capital Expenditures
Capital Expenditures are funds used by Nektar Therapeutics to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Nektar Therapeutics operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Most accounts from Nektar Therapeutics' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Nektar Therapeutics current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nektar Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Nektar Stock, please use our How to Invest in Nektar Therapeutics guide.At this time, Nektar Therapeutics' Total Cashflows From Investing Activities is relatively stable compared to the past year. As of 03/29/2025, Other Cashflows From Investing Activities is likely to grow to about 98.8 M, though Change In Working Capital is likely to grow to (5.9 M).
Nektar Therapeutics cash flow statement Correlations
Click cells to compare fundamentals
Nektar Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Nektar Therapeutics cash flow statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | 102.6M | (173.7M) | 63.0M | (53.0M) | 9.0M | 9.4M | |
| Free Cash Flow | (320.5M) | (427.6M) | (309.7M) | (193.5M) | (177.2M) | (168.3M) | |
| Change In Working Capital | 16.7M | (23.1M) | 492K | (19.8M) | (6.2M) | (5.9M) | |
| Begin Period Cash Flow | 96.4M | 199.0M | 25.2M | 88.2M | 35.3M | 66.7M | |
| Other Cashflows From Financing Activities | 496.2M | 36.2M | 1.5M | 30K | 45.1M | 88.7M | |
| Depreciation | 14.2M | 14.1M | 13.0M | 7.8M | (4.9M) | (4.6M) | |
| Other Non Cash Items | (14.4M) | 17.4M | (9.4M) | 62.2M | (73.5M) | (69.8M) | |
| Capital Expenditures | 7.3M | 15.0M | 5.7M | 865K | 1.5M | 1.4M | |
| Total Cash From Operating Activities | (313.3M) | (412.7M) | (304.0M) | (192.6M) | (175.7M) | (166.9M) | |
| Net Income | (444.4M) | (523.8M) | (368.2M) | (276.1M) | (119.0M) | (124.9M) | |
| Total Cash From Financing Activities | (80.4M) | 36.2M | 1.5M | 30K | 42.1M | 40.0M | |
| End Period Cash Flow | 199.0M | 25.2M | 88.2M | 35.3M | 44.3M | 70.8M | |
| Change To Inventory | (2.6M) | (509K) | (3.4M) | 699K | 497K | 521.9K | |
| Stock Based Compensation | 94.3M | 94.7M | 57.3M | 33.4M | 21.6M | 30.8M | |
| Change To Account Receivables | 1.9M | 12.4M | 16.5M | 4.8M | (3.0M) | (2.9M) | |
| Change To Liabilities | 18.8M | 15.7M | (12.3M) | 2.0M | 1.8M | 1.9M | |
| Total Cashflows From Investing Activities | 206.9M | 496.2M | 202.8M | 365.8M | 420.7M | 441.7M | |
| Sale Purchase Of Stock | 23.4M | 23.4M | 33.2M | 0.0 | (3M) | (2.9M) | |
| Other Cashflows From Investing Activities | 503.5M | 217.8M | 371.5M | 1.2M | 53.2M | 98.8M | |
| Investments | 503.5M | 217.8M | 365.8M | 162.2M | 142.6M | 149.7M | |
| Change Receivables | (25.5M) | 6.4M | 1.9M | 12.4M | 11.2M | 11.7M | |
| Cash And Cash Equivalents Changes | 190.2M | (98.4M) | 102.6M | (173.6M) | (156.3M) | (148.5M) | |
| Cash Flows Other Operating | (57.9M) | (13.7M) | 26.0M | 30.2M | 34.7M | 36.5M | |
| Change To Netincome | 88.5M | 76.0M | 120.1M | 50.7M | 58.3M | 50.1M | |
| Change To Operating Activities | 20.2M | 20.6M | (22.7M) | (14.7M) | (16.9M) | (17.7M) |
Pair Trading with Nektar Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Nektar Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Nektar Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Nektar Stock
| 0.44 | LLY | Eli Lilly | PairCorr |
| 0.44 | SNY | Sanofi ADR | PairCorr |
| 0.41 | AZN | AstraZeneca PLC ADR | PairCorr |
| 0.4 | PLX | Protalix Biotherapeutics | PairCorr |
| 0.36 | BMY | Bristol Myers Squibb | PairCorr |
The ability to find closely correlated positions to Nektar Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Nektar Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Nektar Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Nektar Therapeutics to buy it.
The correlation of Nektar Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Nektar Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Nektar Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Nektar Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Nektar Stock Analysis
When running Nektar Therapeutics' price analysis, check to measure Nektar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nektar Therapeutics is operating at the current time. Most of Nektar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nektar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nektar Therapeutics' price. Additionally, you may evaluate how the addition of Nektar Therapeutics to your portfolios can decrease your overall portfolio volatility.